ImmunityBio shares are trading higher after the company announced that the National Comprehensive Cancer Network has updated its 2026 Clinical Practice Guidelines in Oncology for Bladder Cancer to include ANKTIVA, in combination with Bacillus Calmette-Guérin, for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer with papillary-only disease.